Differential Effectiveness of Antipsychotics in Borderline Personality Disorder
Authors:
- Theo J.M. IngenhovenTITheo J.M. Ingenhoven
- Hugo J. DuivenvoordenHDHugo J. Duivenvoorden
- 1 August 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 31 (4) , 489-496
Abstract
In clinical practice, antipsychotic drugs are widely used in borderline personality disorder (BPD). To evaluate current pharmacological treatment algorithms and guidelines for BPD, the authors reviewed and meta-analyzed studies on the effectiveness of antipsychotics on specific symptom domains in BPD. The literature was searched for placebo-controlled, randomized clinical trials (PC-RCTs) on the effectiveness of antipsychotics regarding cognitive perceptual symptoms, impulsive behavioral dyscontrol, and affective dysregulation (with subdomains depressed mood, anxiety, anger, and mood lability) in BPD. Studies whose primary emphasis was on the treatment of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition schizotypal personality disorder or Axis I disorders were excluded. Meta-analyses were conducted using 11 retrieved studies including 1152 borderline patients. Antipsychotics have a significant effect on cognitive perceptual symptoms (9 PC-RCTs; standardized mean difference [SMD], 0.23) and mood lability (5 PC-RCTs; SMD, 0.20) as well as on global functioning (8 PC-RCTs; SMD, 0.25), but these effects have to be qualified as small. Antipsychotics have a more pronounced effect on anger (9 PC-RCTs; SMD, 0.39). Antipsychotics did not have a significant effect on impulsive behavioral dyscontrol, depressed mood, and anxiety in BPD. Drug therapy tailored to well-defined symptom domains can have beneficial effects in BPD. At short term, antipsychotics can have significant effects on cognitive-perceptual symptoms, anger, and mood lability, but the wide and long-term use of antipsychotics in these patients remains controversial. The findings from this study raise questions on current pharmacological algorithms and clinical guidelines.Keywords
This publication has 30 references indexed in Scilit:
- Pharmacotherapy for borderline personality disorder: NICE guidelineThe British Journal of Psychiatry, 2010
- Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trialsThe British Journal of Psychiatry, 2010
- Effectiveness of Pharmacotherapy for Severe Personality DisordersThe Journal of Clinical Psychiatry, 2009
- P.3.c.038 The effect of quetiapine on psychotic-like symptoms in borderline personality disorder. A placebo-controlled trialEuropean Neuropsychopharmacology, 2008
- Ziprasidone in the Treatment of Borderline Personality DisorderThe Journal of Clinical Psychiatry, 2008
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality DisordersThe World Journal of Biological Psychiatry, 2007
- Pharmacological interventions for people with borderline personality disorder2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Empirical Evidence and Psychotherapy: A Growing Scientific BaseAmerican Journal of Psychiatry, 2001
- Amitriptyline versus Haloperidol in BorderlinesJournal of Clinical Psychopharmacology, 1989